← AstraZeneca PLC (AZN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
AstraZeneca PLC (AZN)
Pharmaceutical Preparations · market cap $256.5B · as of 2026-10-27
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
AstraZeneca PLC (AZN) is a Cambridge, England-headquartered, Swedish-British pharma group with about 96,100 employees and a market cap of roughly $256.5B. Its portfolio spans oncology, cardiovascular, respiratory, immunology, neuroscience and rare disease. Our database shows a very broad pipeline, with acalabrutinib in CLL/SLL as the lead entry, and a dense catalyst calendar from late October through early December 2026, including earnings on 2026-10-30.
The catalyst path
- 2026-11-15 (est.)Phase 2 · Durvalumabimp 7/10
- 2026-11-17 (est.)Phase 2 · AZD0901imp 7/10
- 2026-11-30 (est.)Phase 2 · Tremelimumabimp 7/10
- 2026-12-01 (est.)Phase 2 · Acalabrutinibimp 7/10
- 2026-12-07 (est.)Phase 3 · Eculizumabimp 9/10
- 2026-12-10 (est.)Phase 2 · Baxdrostat/dapagliflozinimp 7/10
- 2026-12-15 (est.)Phase 3 · Durvalumabimp 9/10
- 2026-12-15 (est.)Phase 2 · Olaparibimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ACH-3102 | Phase 2 | Hepatitis C, Chronic |
| AZD1152 | Phase 3 | Acute Myeloid Leukemia |
| AC2993 (exenatide) | Phase 2 | Diabetes Mellitus |
| AZD6234 | Phase 3 | Obesity/Overweight |
| MEDI6570 | Phase 2 | Coronary Heart Disease (CHD) |
| Tremelimumab monotherapy | Phase 2 | Urothelial Bladder Cancer |
| Niraparib plus Abiraterone acetate plus Prednisone | Phase 3 | Metastatic Castration-resistant Prostate Cancer (mCRPC) |
| B - Exenatide | Phase 2 | Diabetes Mellitus, Type 2 |
| ZD1839 | Phase 2 | Mesothelioma |
| Chemotherapy | Phase 3 | Anticancer Treatment |
| Saruparib (AZD5305) | Phase 3 | Ovarian Cancer |
| Ticagrelor Dose 1a + Dose 2a | Phase 2 | Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease |
| Ceftaroline fosamil | Phase 3 | Infections |
| exenatide twice daily | Phase 3 | Type 2 Diabetes Mellitus |
| Ciclesonide nasal | Phase 3 | Rhinitis, Allergic, Perennial |
| Ticagrelor orodispersible tablets | Phase 3 | ST Elevation Myocardial Infarction |
| PwO | Phase 2 | Breast Cancer |
| SBC-103 | Phase 2 | Mucopolysaccharidosis IIIB |
| Paroxetine | Phase 3 | Generalized Anxiety Disorder |
| AZD2265 | Phase 3 | Metastatic Castration-resistant Prostate Cancer |
Price & technical context
3-month
+15.8%
6-month
+2.4%
12-month
+13.9%
52-wk range
$155.62–$209.48
vs 50-day MA
+12.5%
vs 200-day MA
+3.7%
Realized vol
28.4%
Max drawdown
-57.7%
Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AZN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.